Karyopharm y Menarini Group anuncian la designación de medicamento huérfano por parte de la Comisión Europea del selinexor para el tratamiento de la mielofibrosis ...Middle East

NEWTON, Massachusetts, y FLORENCIA, Italia, 2 de noviembre de 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), una empresa farmacéutica en etapa comercial pionera en terapias oncológicas novedosas, y Menarini Group ("Menarini"), una empresa farmacéutica internacional...

Hence then, the article about karyopharm y menarini group anuncian la designacion de medicamento huerfano por parte de la comision europea del selinexor para el tratamiento de la mielofibrosis was published today ( Thursday 03/11/2022 - 04:25 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Karyopharm y Menarini Group anuncian la designación de medicamento huérfano por parte de la Comisión Europea del selinexor para el tratamiento de la mielofibrosis )

Also on site :

• Two dozen killed in Ukrainian strike on Russian New Year’s celebration – governor
• Volunteer in Iran’s Revolutionary Guard reportedly killed during widening protests
• Palestinian Mujahideen Movement Condemns Israeli Enemy& 039;s Prevention of International Organizations from Continuing Their Work